Aravive is a US-based clinical-stage biopharmaceutical company that specializes in developing treatments for various life-threatening diseases, with a particular focus on cancer and fibrosis. The company is known for its lead product, Batiraxcept, which is currently in Phase III clinical trials for platinum-resistant recurrent ovarian cancer. Aravive has also partnered with several other firms, including WuXi Biologics and 3D Medicines, to develop a range of high-affinity bispecific antibodies and other life-saving treatments.